Lesogaberan napadisylate
| Code | Size | Price |
|---|
| TAR-T40572-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lesogaberan (AZD-3355) napadisylate is a potent and selective GABA B receptor agonist with an EC 50 of 8.6 nM for human recombinant GABA B receptors. The affinity ( K i s) of Lesogaberan napadisylate for rat GABA B and GABA A receptors, as measured by displacement of [ 3 H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan napadisylate inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
CAS:
477956-38-0
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Lehmann A, et al. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther. 2009 Nov;331(2):504-12.
Tian J, et al. Repurposing Lesogaberan to Promote Human Islet Cell Survival and ?-Cell Replication. J Diabetes Res. 2017;2017:6403539.